PTI is part of the Knowledge & Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Welcome. If you're a registered user, please log-in. If not, please sign-up.

VIEW AGENDA | DOWNLOAD AGENDA

Mastering Regulatory and Development Strategies for Generics

2-day course | 27 - 28 November 2018

Radisson Blu Edwardian Kenilworth, London

Agenda

Gain a strategic insight into the key requirements for developing generics from a global perspective

view agenda register

Bringing a generic drug to market can be fraught with regulatory challenges and compliance issues. This course will allow the participants to gain a strategic insight into key requirements for developing generics from a global perspective and an overview of the generics market; current trends and practices; and future strategies for regulatory compliance.

Examine the impact of EU and US regulatory approval for generic products
Clarify the criteria for submitting generic applications in Europe and US
Enable creation of development plan for "Right First Time" generics
Assess the major developments in patents and trademarks for global generics
Maximise generic market-share potential
Formulate regulatory strategies to achieve successful regulatory performance and compliance
Pinpoint key developments in market exclusivity

This course has been specifically designed to address the needs of:

Regulatory Affairs Managers/Officers/ Assistants
Compliance Managers
Product RegistrationPersonnel
Project Managers in Regulatory Affairs
Documentation Managers
Key contributors to submission procedures

Andrew Willis

Previously Vice President of Regulatory Affairs and Consulting Services at Catalent Pharma Solutions, Andrew is currently an independent regulatory affairs and pharmaceutical development consultant. Andrew has over 28 years of experience in regulatory affairs and pharmaceutical development, with specific experience of EU and US registrations, CMC regulatory requirements and multiple clinical aspects related to successful registration of drug products. Andrew is considered an expert in lifecycle management and has signifi cant experience in OTC and generic development, as well as global development strategies.

Gain a strategic insight into the key requirements for developing generics from a global perspective

Andrew Willis

You may also be interested in...

Preparing the Quality Module of the CTD

Regulatory Affairs Strategies

Regulatory Affairs in Latin America

Fundamentals of EU Regulatory Affairs - Online Academy

Regulatory Information Management and IDMP Training

eCTD Submissions

US-FDA Drug Submission Procedures

Challenges in Drug/Device Combination Products

Regulatory, Developmental and Manufacturing Challenges for ATMPs

NEW ON-DEMAND TRAINING LIBRARY

Regulatory Affairs Risk Management

Introduction to Regulatory Affairs in the MENA Region

Fundamentals of European Regulatory Affairs

Regulatory Affairs for Clinical Trials

A Practical Guide to Pharmacovigilance

GDPR and Data Protection in the Pharmaceutical Industry

Examining the Q3D Guideline on Elemental Impurities

Module 3 of the Global CTD

Advanced European Regulatory Affairs

Project Management for Regulatory Affairs Professionals

EU & US Requirements for Pharmaceutical Labelling & Package Leaflets

PTI Course Calendar

Filing Variations

Gaining Marketing Authorisations in CIS for Pharmaceuticals and Biotech